Related Experiment Video
Updated: Feb 3, 2026

Extraction of Aqueous Metabolites from Cultured Adherent Cells for Metabolomic Analysis by Capillary Electrophoresis-Mass Spectrometry
Published on: June 9, 2019
A case of dihydropyrimidinase deficiency incidentally detected by urine metabolome analysis
Hiroki Tsuchiya1, Tomoyuki Akiyama1, Tomiko Kuhara2
1Department of Child Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan; Department of Child Neurology, Okayama University Hospital, Okayama, Japan.
Abstract:
Dihydropyrimidinase deficiency is a rare autosomal recessive disease affecting the second step of pyrimidine degradation. It is caused by mutations in the DPYS gene. Only approximately 30 cases have been reported to date, with a phenotypical variability ranging from asymptomatic to severe neurological illness. We report a case of dihydropyrimidinase deficiency incidentally detected by urine metabolome analysis. Gas chromatography-mass spectrometry-based urine metabolomics demonstrated significant elevations of dihydrouracil and dihydrothymine, which were subsequently confirmed by a quantitative analysis using liquid chromatography-tandem mass spectrometry. Genetic testing of the DPYS gene revealed two mutations: a novel mutation (c.175G > T) and a previously reported mutation (c.1469G > A). Dihydropyrimidinase deficiency is probably underdiagnosed, considering its wide phenotypical variability, nonspecific neurological presentations, and an estimated prevalence of 2/20,000. As severe 5-fluorouracil-associated toxicity has been reported in patients and carriers of congenital pyrimidine metabolic disorders, urinary pyrimidine analysis should be considered for those who will undergo 5-fluorouracil treatment.
Insights
Dihydropyrimidinase deficiency, a rare genetic disorder, was identified through urine metabolomics. Early detection via urinary pyrimidine analysis is crucial, especially before 5-fluorouracil treatment, due to potential toxicity.
Area of Science:
- Biochemistry
- Genetics
- Metabolic Disorders
Background:
- Dihydropyrimidinase deficiency is a rare autosomal recessive disorder impacting pyrimidine degradation.
- Caused by mutations in the DPYS gene, it presents with variable phenotypes, from asymptomatic to severe neurological illness.
Observation:
- A case of dihydropyrimidinase deficiency was incidentally discovered using urine metabolome analysis.
- Elevated levels of dihydrouracil and dihydrothymine were detected via gas chromatography-mass spectrometry and confirmed with liquid chromatography-tandem mass spectrometry.
Findings:
- Genetic analysis identified a novel (c.175G>T) and a known (c.1469G>A) mutation in the DPYS gene.
- The study suggests dihydropyrimidinase deficiency may be underdiagnosed due to its variable presentation and nonspecific neurological symptoms.
Implications:
- Urinary pyrimidine analysis is recommended for individuals undergoing 5-fluorouracil treatment, particularly those with potential pyrimidine metabolic disorders.
- Prompt diagnosis and monitoring are essential for managing patients with dihydropyrimidinase deficiency and preventing severe drug-associated toxicity.
Related Concept Videos
Filtration and Urine Formation
Urine Studies II: Urine Culture and Sensitivity Test
Physiology of Urine Formation
Glomerular Filtration
The first stage in urine formation is glomerular filtration. Each kidney contains approximately 1 million nephrons, the functional units of filtration, with a...
Formation of Concentrated Urine
Urine Studies I: Urinalysis
Formation of Dilute Urine
Filtrate Osmolarity in the PCT
Initially, as the filtrate passes through the proximal convoluted tubule (PCT), its...

